Scandinavian ChemoTech receives approval from the US Patent Office
Scandinavian ChemoTech AB announces today that the Company has received approval from the US Patent Office for its innovation for the treatment of pain caused by metastases in the spine and skeleton. This innovation is also applicable to the treatment of deep-seated tumours, which is another of the Company's development projects.The patent is based on the same innovation that was approved in Europe in July 2021 and includes a specially developed electrode as well as unique dynamic properties. These functions are already implemented in the TSE platform and are intended to treat tumours